News Image

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Provided By GlobeNewswire

Last update: Feb 20, 2024

CHAPEL HILL, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

Read more at globenewswire.com

TENAX THERAPEUTICS INC

NASDAQ:TENX (2/21/2025, 8:00:01 PM)

After market: 6.4185 -0.33 (-4.91%)

6.75

+0.62 (+10.11%)



Find more stocks in the Stock Screener

Follow ChartMill for more